Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy

John W Day, Jerry R Mendell, Eugenio Mercuri, Richard S Finkel, Kevin A Strauss, Aaron Kleyn, Sitra Tauscher-Wisniewski, Francis Fonyuy Tukov, Sandra P Reyna, Deepa H Chand, John W Day, Jerry R Mendell, Eugenio Mercuri, Richard S Finkel, Kevin A Strauss, Aaron Kleyn, Sitra Tauscher-Wisniewski, Francis Fonyuy Tukov, Sandra P Reyna, Deepa H Chand

Abstract

Introduction: This is the first description of safety data for intravenous onasemnogene abeparvovec, the only approved systemically administered gene-replacement therapy for spinal muscular atrophy.

Objective: We comprehensively assessed the safety of intravenous onasemnogene abeparvovec from preclinical studies, clinical studies, and postmarketing data.

Methods: Single-dose toxicity studies were performed in neonatal mice and juvenile or neonatal cynomolgus nonhuman primates (NHPs). Data presented are from a composite of preclinical studies, seven clinical trials, and postmarketing sources (clinical trials, n = 102 patients; postmarketing surveillance, n = 665 reported adverse event [AE] cases). In clinical trials, safety was assessed through AE monitoring, vital-sign and cardiac assessments, laboratory evaluations, physical examinations, and concomitant medication use. AE reporting and available objective clinical data from postmarketing programs were evaluated.

Results: The main target organs of toxicity in mice were the heart and liver. Dorsal root ganglia (DRG) inflammation was observed in NHPs. Patients exhibited no evidence of sensory neuropathy upon clinical examination. In clinical trials, 101/102 patients experienced at least one treatment-emergent AE. In total, 50 patients experienced serious AEs, including 11 considered treatment related. AEs consistent with hepatotoxicity resolved with prednisolone in clinical trials. Transient decreases in mean platelet count were detected but were without bleeding complications. Thrombotic microangiopathy (TMA) was observed in the postmarketing setting. No evidence of intracardiac thrombi was observed for NHPs or patients.

Conclusions: Risks associated with onasemnogene abeparvovec can be anticipated, monitored, and managed. Hepatotoxicity events resolved with prednisolone. Thrombocytopenia was transient. TMA may require medical intervention. Important potential risks include cardiac AEs and DRG toxicity.

Trial registration: ClinicalTrials.gov NCT02122952 NCT03306277 NCT03505099 NCT03461289 NCT03837184 NCT03421977 NCT04042025.

Conflict of interest statement

John Day, Jerry Mendell, Eugenio Mercuri, Richard Finkel, and Kevin A. Strauss were study investigators in onasemnogene abeparvovec clinical trials. Aaron Kleyn, Sitra Tauscher-Wisniewski, Francis Fonyuy Tukov, Sandra P. Reyna, and Deepa H. Chand are employees of Novartis Gene Therapies, Inc., the manufacturer of onasemnogene abeparvovec.

© 2021. The Author(s).

References

    1. Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20:27–32. doi: 10.1038/ejhg.2011.134.
    1. Kolb S, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33:831–846. doi: 10.1016/j.ncl.2015.07.004.
    1. Darras BT, Monani UR, De Vivo DC, et al. et al. Genetic disorders affecting the motor neuron: spinal muscular atrophy. In: Swaiman KF, et al., editors. Swaiman’s pediatric neurology: principles and practice. 6. Edinburgh: Elsevier; 2017. pp. 1057–1064.
    1. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713–1722. doi: 10.1056/NEJMoa1706198.
    1. Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy with two copies of SMN2 (STR1VE): an open-label, single-arm, phase 3 study. Lancet Neurol. 2021;20:284–293. doi: 10.1016/S1474-4422(21)00001-6.
    1. Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74:560–566. doi: 10.1016/j.jhep.2020.11.001.
    1. Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2021;231:265–268. doi: 10.1016/j.jpeds.2020.11.054.
    1. European Medicines Agency. Assessment report: Zolgensma. . Accessed 26 Apr 2021.
    1. Al-Zaidy SA, Kolb SJ, Lowes L, et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis. 2019;6:307–317. doi: 10.3233/JND-190403.
    1. Strauss K, et al. Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with 2 copies of SMN2. Neurology. 2021;96:S15.
    1. Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. (in press).
    1. Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78:834–841. doi: 10.1001/jamaneurol.2021.1272.
    1. Sands MS. AAV-mediated liver-directed gene therapy methods. Methods Mol Biol. 2011;807:141–157. doi: 10.1007/978-1-61779-370-7_6.
    1. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342–347. doi: 10.1038/nm1358.
    1. Feldman AG, Parsons JA, Dutmer CM, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225:252–258. doi: 10.1016/j.jpeds.2020.05.044.
    1. Kichula EA, Proud CM, Farrar MA, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021 doi: 10.1002/mus.27363.
    1. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangiopathies: unraveling Ariadne’s thread into the labyrinth of complement Therapeutics. Front Immunol. 2019;10:337. doi: 10.3389/fimmu.2019.00337.
    1. Chen BD, He CH, Chen XC, et al. Targeting transgene to the heart and liver with AAV9 by different promoters. Clin Exp Pharmacol Physiol. 2015;42:1108–1117. doi: 10.1111/1440-1681.12453.
    1. Bauer R, Enns H, Jungmann A, et al. Various effects of AAV9-mediated βARKct gene therapy on the heart in dystrophin-deficient (mdx) mice and δ-sarcoglycan-deficient (Sgcd-/-) mice. Neuromuscul Disord. 2019;29:231–241. doi: 10.1016/j.nmd.2018.12.006.
    1. Yoldaş T, Örün UA. What is the significance of elevated troponin I in children and adolescents? A diagnostic approach. Pediatr Cardiol. 2019;40:1638–1644. doi: 10.1007/s00246-019-02198-w.
    1. Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29:285–298. doi: 10.1089/hum.2018.015.
    1. Hordeaux J, Buza EL, Dyer C, et al. Adeno-associated virus-induced dorsal root ganglion pathology. Hum Gen Ther. 2020;31:808–818. doi: 10.1089/hum.2020.167.
    1. Shorrock HK, Gillingwater TH, Groen EJN. Molecular mechanisms underlying sensory-motor circuit dysfunction in SMA. Front Mol Neurosci. 2019;12:59. doi: 10.3389/fnmol.2019.00059.
    1. Yonekawa T, Komaki H, Saito Y, et al. Peripheral nerve abnormalities in pediatric patients with spinal muscular atrophy. Brain Dev. 2013;35:165–171. doi: 10.1016/j.braindev.2012.03.009.
    1. Yuan P, Jiang L. Clinical characteristics of three subtypes of spinal muscular atrophy in children. Brain Dev. 2015;37:537–541. doi: 10.1016/j.braindev.2014.08.007.
    1. Ven AA, Van Hees JG, Stappaerts KH. Effect of size and pressure of surface recording electrodes on amplitude of sensory nerve action potentials. Muscle Nerve. 2004;30:234–238. doi: 10.1002/mus.20071.
    1. Farrar MA, Vucic S, Johnston HM, et al. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr. 2013;162:155–159. doi: 10.1016/j.jpeds.2012.05.067.
    1. Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103–115. doi: 10.1016/j.nmd.2017.11.005.
    1. Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197–207. doi: 10.1016/j.nmd.2017.11.004.
    1. Oskoui M, Levy G, Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931–1936. doi: 10.1212/01.wnl.0000290830.40544.b9.
    1. Borkowska J, Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, et al. Early infantile form of spinal muscular atrophy (Werdnig-Hoffmann disease) with prolonged survival. Folia Neuropathol. 2002;40:19–26.
    1. Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38–43. doi: 10.1016/j.ejpn.2020.07.001.
    1. Narver HL, Kong L, Burnett BG, et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann Neurol. 2008;64:465–470. doi: 10.1002/ana.21449.
    1. AveXis. Zolgensma prescribing information. 2021. . Accessed 28 Apr 2021.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅